Grifols, S.a. (0RDV.IL) Stock
Grifols, S.a.

Company profile
Grifols reported revenue of 7.52 billion EUR for fiscal year 2025, up 4.3% from fiscal year 2024, and net income of 402.00 million EUR. That is a net profit margin of 5.3% for fiscal year 2025. In Q2 2026 (the quarter ended June 30, 2026) revenue was 1.87 billion EUR, down 0.9% from a year before. In Q2 2026 it reported net income of 155.00 million EUR, against net income of 117.06 million EUR a year earlier. Our analysis of its filings shows revenue growing from 6.59 billion EUR in fiscal year 2023 to 7.52 billion EUR in fiscal year 2025, 6.8% a year on average. Grifols reports about 23,631 full-time employees.
What stands out
- Net income more than doubled in fiscal year 2025, from 156.92 million EUR in fiscal year 2024.
- Revenue and net income in fiscal year 2025 were the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Grifols, S.a.
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product. The Diagnostic segment offers transfusion medicine, which includes Procleix Panther systems/Procleix Panther with Automation Ready technology, Automated NAT blood screening systems, assays, software, WADiana/Erytra/Erytra Eflexys analyzers, BLOODchip ID/IDCore/IDHPA/IDRHD/IDCORE/BIDS, and antigens; and clinical and diagnostics products, such as Promonitor and Alpha1D. The Bio Supplies segment provides human biological materials for life sciences research and the development and manufacturing of pharmaceutical and diagnostic products. The Others segment offers healthcare solutions, which provides services and manufactures products, including parenteral solutions, robotics, and software used by hospitals, blood banks, plasma collection centers and other healthcare systems. The company's products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. Grifols, S.A. has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products, and with GIANT and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Leadership
- Thomas H. Glanzmann — CEO & Exec. Chairman, 64
- Alfredo Arroyo Guerra — CFO & VP, 64
- Víctor Grifols Deu — COO & Director, 45
- Raimon Grifols Roura — Chief Corp. Officer & Vice-Chairman, 58
- David Ian Bell — Chief Corp. Devel., Legal & Data Protection Officer, 68
In the news
- GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?
- European Equities Traded in the US as American Depositary Receipts Drop in Thursday Trading
- GRFS or SDZNY: Which Is the Better Value Stock Right Now?
- European Equities Traded in the US as American Depositary Receipts Edge Higher in Tuesday Trading
How much revenue does Grifols make?
Grifols reported 7.52 billion EUR in revenue for fiscal year 2025, up 4.3% from 7.21 billion EUR in fiscal year 2024. In Q2 2026 revenue was 1.87 billion EUR.
What companies are similar to Grifols?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (0QFP.IL), UCB SA (0NZT.IL), Hikma Pharmaceuticals PLC (HIK.L), International Biotechnology Ord (IBT.L).
Has Grifols made a profit in recent years?
Net income by fiscal year: FY2021, 188.73 million EUR; FY2022, 185.04 million EUR; FY2023, 42.32 million EUR; FY2024, 156.92 million EUR; FY2025, 402.00 million EUR. It was profitable in each of these years.
How has Grifols' revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 4.93 billion EUR; FY2022, 6.06 billion EUR; FY2023, 6.59 billion EUR; FY2024, 7.21 billion EUR; FY2025, 7.52 billion EUR.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Grifols, S.a. (0RDV.IL)”, data as of Jun 30, 2026, https://dataporium.tech/stocks/0RDV.IL